In a filing, VBI Vaccines Inc. revealed its Director GILLIS STEVEN acquired Company’s shares for reported $1.0 million on Jul 10. In the deal valued at $1.65 per share,609,090 shares were bought. As a result of this transaction, GILLIS STEVEN now holds 1,043,292 shares worth roughly $ 1.29 million.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Then, PERCEPTIVE ADVISORS LLC sold 4,251,563 shares, generating $467,672 in total proceeds. Upon selling the shares at $0.11, the 10% Owner now owns 41,440,729 shares.
Before that, PERCEPTIVE ADVISORS LLC sold 1,832,563 shares. VBI Vaccines Inc. shares valued at $238,233 were divested by the 10% Owner at a price of $0.13 per share. As a result of the transaction, PERCEPTIVE ADVISORS LLC now holds 45,691,816 shares, worth roughly $56.66 million.
Raymond James downgraded its VBI Vaccines Inc. [VBIV] rating to an Outperform from a a Strong buy in a research note published on Friday, November 11, 2022; the price target was decreased to $2 from $5. PT values the company’s stock at a premium of 38.0 to its Friday closing price.
Price Performance Review of VBIV
On Friday, VBI Vaccines Inc. [NASDAQ:VBIV] saw its stock jump 1.64% to $1.24. On the same session, the stock had its day’s lowest price of $1.20, but rose to a high of $1.26. Over the last five days, the stock has gained 0.81%. VBI Vaccines Inc. shares have fallen nearly -89.43% since the year began. Nevertheless, the stocks have fallen -95.38% over the past one year. While a 52-week high of $28.18 was reached on 01/18/23, a 52-week low of $1.08 was recorded on 07/06/23. SMA at 50 days reached $1.4518, while 200 days put it at $8.0609. A total of 73189.0 shares were traded, compared to the trading of 0.15 million shares in the previous session.
Levels Of Support And Resistance For VBIV Stock
The 24-hour chart illustrates a support level at 1.2067, which if violated will result in even more drops to 1.1733. On the upside, there is a resistance level at 1.2667. A further resistance level may holdings at 1.2933. The Relative Strength Index (RSI) on the 14-day chart is 42.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0157, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.54%. Stochastics %K at 24.59% indicates the stock is a holding.
How much short interest is there in VBI Vaccines Inc.?
A steep rise in short interest was recorded in VBI Vaccines Inc. stocks on Aug 14, 2023, dropping by -0.25 million shares to a total of 0.16 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.4 million shares. There was a decline of -157.26%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 0.75% of the overall stock float, the days-to-cover ratio (short ratio) fell to 0.31.
VBI Vaccines Inc. [VBIV] – Who Are The Largest Shareholders?
In filings from Perceptive Advisors LLC, it is revealed that the company now owns 1,381,355 shares, or roughly 6.04% of the outstanding VBIV shares. In other words, the investor’s shares have fallen by -363,128 from its previous 13-F filing of 1744483.0. Additionally, BlackRock Fund Advisors decreased -71.48% of its stake after which the total value it holdings stand at $146,465, while Cambridge Investment Research Adv reduced -6.55% of its stake to hold $0.13 million in the firm. Over the last quarter, Millennium Management LLC purchased 88,664 shares of VBI Vaccines Inc., while Geode Capital Management LLC bought -62,699 shares. At present, General American Investors Co., I is holding 62,583 shares valued at $81984.0. The Vanguard Group, Inc. owned 59,707 shares of the company at the time of its most recent 13F filing, worth $78216.0.
According to FactSet, VBI Vaccines Inc.’s share price will average $6.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 391.8 percent from its previous closing price of $1.22. Analysts expect VBI Vaccines Inc. stock to reach the higher price of $6.00, while the lowest price estimate is $6.00. However, 1 analyst have rated VBIV stock as an Overweight in their predictions for 2023.